Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announces the final closing of its rights
offering, which expired on March 8, 2017 and raised aggregate gross
proceeds of $10.8 million from the sale of 3,611,764 ordinary shares.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q, as
well as the Registration Statement on Form S-1 declared effective on
December 5, 2016. Accordingly, readers are cautioned that any such
forward-looking statements are not guarantees and are subject to certain
risks, uncertainties and assumptions that are difficult to predict.
Although Presbia believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements. Unless
otherwise required by law, Presbia also disclaims any obligation to
update its view of any such risks or uncertainties or to announce
publicly the result of any revisions to the forward-looking statements
made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170313006270/en/
Jarett Fenton, 949-502-7036
Source: Presbia PLC
News Provided by Acquire Media